China Resources Sanjiu Medical & Pharmaceutical Co (000999) H1 2024 earnings summary

Executive summary

• Achieved revenue of ¥14.11 billion in H1 2024, up 7.30% year-over-year, with net profit attributable to shareholders rising 27.77% to ¥2.40 billion.

• Cash flow from operating activities increased 33.36% year-over-year to ¥2.36 billion.

• Growth driven by CHC (consumer health) business, which rose 14.00% year-over-year, offsetting a 13.07% decline in prescription drug revenue.

• Maintained strong brand and channel advantages, with continued investment in R&D and digital transformation.

Financial highlights

• Revenue: ¥14.11 billion, up 7.30% year-over-year.

• Net profit attributable to shareholders: ¥2.40 billion, up 27.77% year-over-year.

• Operating cash flow: ¥2.36 billion, up 33.36% year-over-year.

• Basic and diluted EPS: ¥1.87, up 27.21% year-over-year.

• Gross margin for CHC business: 62.87%; for prescription drugs: 47.14%.

Outlook and guidance

• Full-year revenue expected to outpace industry average, targeting double-digit growth.

• Management notes potential uncertainties from disease incidence, policy changes, and external environment.

• Company has specific countermeasures for risks such as changes in respiratory disease incidence and policy-driven procurement.